Acosta-Ramón V, Estíbaliz López de Goicoecha-Saiz M, Pariente-Rodrigo E

Language: Spanish
References: 17
Page: 149-155
PDF size: 149.08 Kb.

ABSTRACT

Paragangliomas are neuroendocrine tumors emerging from the extra-adrenal autonomic paraganglia, which are small organs formed by embryonic neural crestderived cells with catecholamine-secreting capacity. Paragangliomas are closely linked to pheochromocytomas because they cannot be differentiated at cell level and often share the same clinical manifestations such as hypertension, episodic headache, sweating and tachycardia. The diagnosis of these tumors is important because of risk of becoming malignant, the implications of other related neoplasias and the possibility of making genetic studies to detect other cases in the same family. The objective of this article was to make an abstract about epidemiology, clinical manifestations, diagnostic tests and treatment of these tumors. This is the case of a young Black female who was diagnosed with paraganglioma.

REFERENCES

1. Pinto A, Barletta JA. Adrenal Tumors in Adults. Surg Pathol Clin. 2015 Dec;8(4):725-49.

2. Young WF. Médula suprarrenal, catecolaminas y feocromocitoma. En: Cecil y Goldman. Tratado de medicina interna. 24ª ed. Madrid: Elsevier; 2013. p. 1474-9.

3. Kiernan C, Solórzano C. Pheochromocytoma and Paraganglioma. Surg Oncol Clin N Am. 2016;25(1):119-38.

4. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacchè M, Mori L, et al. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94:1541-7.

5. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26:551-6.

6. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: The expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;95:1196-204.

7. Maher ER, Eng C. The pressure rises: update on the genetics of pheochromocytoma. Hum Mol Genet. 2002;11:2347-54.

8. Bernal C, Alcázar JM. Feocromocitoma: presentación clínica. Diagnóstico y tratamiento. Hipertensión. 2006;23(6):173-83.

9. Landsberg L, Young JB. Feocromocitoma. En: Harrison TR. Principios de Medicina Interna. 14ª ed. Madrid: McGraw-Hill Interamericana; 1998. p. 2337.

10. Herbert C, Sippel R, O'Dorisio M, Vinik A, Lloyd R, Pacak K. The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer. Pancreas. 2010;39(6):775-83.

11. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287:1427-34.

12. Van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab. 2010;95:209-14.

13. Manger WM, Eisenhofer G. Pheocrhomocytoma: diagnosis and management update. Curr Hypert Rep. 2004;6:477-84.

14. Taieb D, Sebag F, Hubbard JG, Mundler O, Henry JF, Conte-Devolx B. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial pheochromocytoma? Clin Endocrinol. 2004;61:102-8.

15. Cascon A, Pita G, Burnichon N, Landa I, López-Jiménez E, Montero-Conde C, et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab. 2009;94:1701-5.

16. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315-29.

17. Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665-75.